LAVAL, QC, June 15, 2020 /CNW/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business,
Salix Pharmaceuticals ("Salix"), one of the largest specialty
pharmaceutical companies in the world committed to the prevention
and treatment of gastrointestinal (GI) diseases, today announced
the recipients of the inaugural Salix Gastrointestinal Health
Scholars Program. Ten outstanding students living with GI
disease who are pursuing their higher education goals will each
receive a $10,000 scholarship
award.
"At Salix, we understand the complexities of managing GI
disease. We created the Salix Gastrointestinal Health Scholars
Program to recognize students who are working diligently to achieve
their higher educational goals while living with the challenges of
a GI disease," said Robert Spurr, president, Salix. "We are
inspired by the incredible resiliency and determination each of our
winners has displayed in pursuit of their education."
The 2020 honorees were selected from more than 100 applications,
based in part on essays sharing their experiences pursuing their
education while living with a gastrointestinal condition. In their
essays, applicants also shared the role their gastroenterologist,
primary care physician or allied health care professional played in
helping them reach their goals. The applications were reviewed by
an independent panel of judges.
The Salix Gastrointestinal Health Scholars Program recognizes
students across a wide range of educational pursuits, with
scholarship awards in four categories, including the Undergraduate
Scholar Awards for those pursuing undergraduate degrees; the
Graduate Scholar Awards for those pursuing graduate degrees; the
Working Parent's Scholar Award for working parents pursuing
undergraduate, vocational/technical or graduate degrees; and the
Single Parent's Scholar Award for single parents pursuing
undergraduate, vocational/technical or graduate degrees.
The 2020 Salix Gastrointestinal Health Scholars Program
recipients are:
- Undergraduate Scholar Awards
-
- Jenny Peters, Smyrna, Tenn. – The University of Alabama
- Julia Piligian, South Hadley, Mass. – University of Massachusetts Lowell
- Kyla Sorensen, Seattle, Wash. – Western
Washington University
- Ryan Soto, Cibolo, Texas – Trinity
University
- Graduate Scholar Awards
-
- Jakob Ozer, Needham, Mass. – Boston
University
- Jocelyn Perez, Revere, Mass. – Columbia
University
- Natacha Richemond, Atlanta, Ga. – The George
Washington University
- Samin Panahi, Bethesda, Md. – University of Maryland
- Working Parent's Scholar Award
-
- Audriana Duvall, Baltimore, Md. – The University of Baltimore
- Single Parent's Scholar Award
-
- LaQuenta Baker, Helena, Ark. – Phillips
Community College of the University of Arkansas
To learn more about the Salix Gastrointestinal Health Scholars
Program, visit www.Salix.com/Scholarship. The 2021 Salix
Gastrointestinal Health Scholars Program will begin accepting
applications in November 2020.
About the Salix Gastrointestinal Health Scholars
Program
The Salix Gastrointestinal Health Scholars Program,
which is funded through the Bausch Foundation, is aimed at
providing financial support to outstanding students who have not
allowed GI disease to stand in the way of their academic
achievements.
About the Bausch Foundation
The Bausch Foundation was
established in 2017 to improve the lives of patients globally by
providing access to safe, effective medicines and by financially
supporting health care education and causes around the
world. Since its inception, the Bausch Foundation has
contributed millions of dollars' worth of financial and product
donations to global charitable health organizations.
About Salix
Salix Pharmaceuticals is one of the
largest specialty pharmaceutical companies in the world committed
to the prevention and treatment of gastrointestinal diseases. For
30 years, Salix has licensed, developed, and marketed innovative
products to improve patients' lives and arm healthcare providers
with life-changing solutions for many chronic and debilitating
conditions. Salix currently markets its product line to U.S. health
care providers through an expanded sales force that focuses on
gastroenterology, hepatology, pain specialists and primary care.
Salix is headquartered in Bridgewater,
N.J.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in the Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
SAL.0098.USA.20
©2020 Salix Pharmaceuticals or its affiliates.
Investor
Contact:
|
|
|
|
|
|
|
Media
Contact:
|
Arthur
Shannon
|
|
|
|
|
|
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
|
|
|
|
|
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
|
|
|
|
|
|
908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Karen Paff
|
|
|
|
|
|
|
|
karen.paff@salix.com
|
|
|
|
|
|
|
|
(908)
927-1190
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/salix-announces-inaugural-salix-gastrointestinal-health-scholars-program-recipients-301076570.html
SOURCE Bausch Health Companies Inc.